Get the Stockscreener App
11.93
3.38%
0.39
Pre-market:
11.71
-0.22
-1.84%
Syndax Pharmaceuticals Inc stock is traded at $11.93, with a volume of 2.47M.
It is up +3.38% in the last 24 hours and down -12.98% over the past month.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
See More
Previous Close:
$11.54
Open:
$11.35
24h Volume:
2.47M
Relative Volume:
1.23
Market Cap:
$967.13M
Revenue:
$139.71M
Net Income/Loss:
$-209.36M
P/E Ratio:
-4.0304
EPS:
-2.96
Net Cash Flow:
$-160.60M
1W Performance:
+6.14%
1M Performance:
-12.98%
6M Performance:
-38.91%
1Y Performance:
-42.64%
1-Day Range:
$11.20
$12.48
1-Week Range:
$10.81
$12.48
52-Week Range:
$9.66
$25.07
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Name
Syndax Pharmaceuticals Inc
Sector
Industry
Phone
781-419-1400
Address
35 GATEHOUSE DRIVE, WALTHAM, MA
Compare SNDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
11.93 | 967.13M | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| Jun-28-24 | Initiated | Jefferies | Buy |
| Jan-31-24 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Oct-25-23 | Initiated | BofA Securities | Buy |
| Oct-11-23 | Initiated | Goldman | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jul-11-23 | Initiated | Guggenheim | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jan-03-23 | Initiated | JP Morgan | Overweight |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Apr-11-22 | Initiated | H.C. Wainwright | Buy |
| Feb-15-22 | Initiated | Goldman | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-25-21 | Initiated | Citigroup | Buy |
| Feb-18-21 | Initiated | B. Riley Securities | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| May-22-20 | Upgrade | Citigroup | Neutral → Buy |
| May-22-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-18-20 | Downgrade | Citigroup | Buy → Neutral |
| May-11-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-08-19 | Reiterated | H.C. Wainwright | Buy |
| Jan-04-19 | Initiated | Robert W. Baird | Outperform |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Mar-16-17 | Initiated | FBR & Co. | Outperform |
| Mar-02-17 | Initiated | Instinet | Buy |
| Oct-07-16 | Initiated | Guggenheim | Buy |
| Mar-28-16 | Initiated | Citigroup | Buy |
| Mar-28-16 | Initiated | JMP Securities | Mkt Outperform |
| Mar-28-16 | Initiated | Morgan Stanley | Overweight |
View All
Syndax Pharmaceuticals Inc Stock (SNDX) Latest News
Renaissance Technologies LLC Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Jump Financial LLC Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Altium Capital Management LLC Makes New $4.89 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Walleye Capital LLC Has $4.82 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
(SNDX) On The My Stocks Page - news.stocktradersdaily.com
Sei Investments Co. Lowers Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
StockNews.com Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to "Sell" - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by ExodusPoint Capital Management LP - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 6.6%Here's What Happened - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 52-Week LowHere's Why - MarketBeat
Sei Investments Co. Sells 35,414 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Barclays Adjusts Price Target for Syndax (SNDX) Ahead of Q1 Earnings | SNDX Stock News - GuruFocus
Vanguard Group Inc. Sells 5,006 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Rhenman & Partners Asset Management AB - MarketBeat
Trexquant Investment LP Buys 437,859 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Bryce Point Capital LLC Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Raised to “Sell” at StockNews.com - Defense World
SNDX stock touches 52-week low at $10.14 amid market challenges By Investing.com - Investing.com South Africa
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Wellington Management Group LLP - MarketBeat
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - The Globe and Mail
Syndax at Stifel Forum: Strategic Drug Launches By Investing.com - Investing.com Canada
Corebridge Financial Inc. Has $540,000 Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
KLP Kapitalforvaltning AS Acquires New Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Syndax Pharmaceuticals: Down But Not Out (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading 4.7% HigherStill a Buy? - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Increased to Sell at StockNews.com - MarketBeat
Axiom Investors LLC DE Sells 62,418 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 12-Month LowWhat's Next? - MarketBeat
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 7.5%Here's Why - MarketBeat
How the (SNDX) price action is used to our Advantage - news.stocktradersdaily.com
Syndax Pharmaceuticals Inc Stock (SNDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
4.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):